Novo Nordisk A/S (NVO) on Decifer Markets

Why it ranks here

• Sales are growing about 6% a year, faster than 24 in 100 companies we measure.
• It keeps about 9 cents of every sales dollar as cash, safer than 66 in 100 companies we measure.
• It earns about 30% a year on the money put into the business, better than 94 in 100 companies we measure.

The current read

The evidence on NVO lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full NVO research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.